Related references
Note: Only part of the references are listed.Generation and validation of structurally defined antibody-siRNA conjugates
Alex R. Nanna et al.
NUCLEIC ACIDS RESEARCH (2020)
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Leonard Jeff Harris et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The current state and future directions of RNAi-based therapeutics
Ryan L. Setten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo
Annabelle Biscans et al.
NUCLEIC ACIDS RESEARCH (2019)
Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies
Alex F. Herrera et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Advanced siRNA Designs Further Improve In Vivo Performance of GaINAc-siRNA Conjugates
Donald J. Foster et al.
MOLECULAR THERAPY (2018)
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
Matthew R. Hassler et al.
NUCLEIC ACIDS RESEARCH (2018)
Journey of siRNA: Clinical Developments and Targeted Delivery
Rahul R. Nikam et al.
NUCLEIC ACID THERAPEUTICS (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
C. Ammala et al.
SCIENCE ADVANCES (2018)
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Jan A. Burger et al.
NATURE REVIEWS CANCER (2018)
Autoimmunity checkpoints as therapeutic targets in B cell malignancies
Markus Muschen
NATURE REVIEWS CANCER (2018)
CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells
Wenjie Peng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chiranjib Chakraborty et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Drugging the 'undruggable' cancer targets
Chi V. Dang et al.
NATURE REVIEWS CANCER (2017)
Synthesis and biological evaluation of sialyl-oligonucleotide conjugates targeting leukocyte B trans-membranal receptor CD22 as delivery agents for nucleic acid drugs
Gabrielle St-Pierre et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Tsukasa Sugo et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes
Thazha P. Prakash et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
M. Pfeifer et al.
LEUKEMIA (2015)
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates
Trinna L. Cuellar et al.
NUCLEIC ACIDS RESEARCH (2015)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
RNAi Therapies: Drugging the Undruggable
Sherry Y. Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas
Cory D. Rillahan et al.
CHEMICAL SCIENCE (2014)
Siglec-mediated regulation of immune cell function in disease
Matthew S. Macauley et al.
NATURE REVIEWS IMMUNOLOGY (2014)
CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells
Mary K. O'Reilly et al.
JOURNAL OF IMMUNOLOGY (2011)
Anti-CD22 Antibody Targeting of pH-responsive Micelles Enhances Small Interfering RNA Delivery and Gene Silencing in Lymphoma Cells
Maria C. Palanca-Wessels et al.
MOLECULAR THERAPY (2011)
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
A. G. Polson et al.
LEUKEMIA (2010)
Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA
CR Allerson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Share Paper
